Lungenkrebszentrum

Sie möchten einen Patienten mit Lungenkarzinom oder Verdacht auf Lungenkarzinom bei uns in der Ambulanzsprechstunde vorstellen? Bitte wenden Sie sich an unser MVZ Prof. Schütte unter der Telefonnummer 0345/5591451. Die Tumorsprechstunde erfolgt täglich von 10-12 Uhr. 

Gerne können Sie auch Patienten stationär einweisen. Neben unserer pneumologisch-onkologischen Station B3, haben wir auch eine zertifizierte Palliativstation zur Durchführung von palliativmedizinischen Komplexbehandlungen. Zur Patienteneinweisung rufen Sie gerne in unserem Sekretariat bei Frau Smok-Hartung unter der Telefonnummer 0345/5591440 an. 

Natürlich bieten wir Ihnen auch die Patientenvorstellung in unserem interdisziplinären Tumorboard an. Unsere Tumorkonferenz findet wöchentlich montags von 15:15 Uhr bis 18 Uhr statt. Anmeldungen können über unsere Cloud jeweils bis montags früh 08:30 Uhr erfolgen. Hierzu wenden Sie sich gerne an unsere Dokumentarin Frau Elisa Schweizer unter der Telefonnummer 0345/5591466. 

Als Lungenkrebszentrum bieten wir eine Vielzahl von interventionellen klinischen Studien an. Sollten Sie Fragen oder geeignete Patienten haben die eingeschlossen werden sollen, so kontaktieren Sie uns gerne per E-Mail unter studiensekretariat.halle@martha-maria.de. 

NSCLC – operabel – perioperative Therapie

MSD; MK-2870-019

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

 

Lokal fortgeschrittenes NSCLC (Stadium III inoperabel), PD-L1 positiv

AstraZeneca; Prot.D9073C00001; Pacific-8

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab in Participants with Locally Advanced (Stage III), Unresectable NSCLC Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (Pacific-8)

 

NSCLC Stadium IV – palliativ; Erstlinientherapie

Samsung Bioepis; Prot. SB27 – 3004

A phase III randomised, double-blilnd, multicentre study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 (proposed Pembrolizumab biosimilar) and Keytruda in subjects with metastatic non-squamous non-small cell lung cancer.

Lillly; Prot. J3M-MC-JZQB; SUNRAY-01

A global pivotal study in participants with KRAS G12C-Mutant, locally advanced or metastatic non-small cell lung cancer comparing first-line treatment of LY3537982 and Pembrolizumab versus Placebo and Pembrolizumab in those with PD-L1 expression >50 % or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs. Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 expression 

AstraZeneca; Prot.D798AC00001; eVOLVE Lung02

A phase III, two-arm, parallel, randomized,multi-center, open-label, global study to determine the efficacy of Volrustomig (MEDI5752) plus chemotherapy versus Pembrolizumab plus chemotherapy for first-line treatment of patients with metastatic non-small cell lung cancer (mNSCLC)

MSD; Prot. MSD-MK3475-D46; EVOKE-03

An open-label, multicenter, phase 3 randomized, active-comparator-controlled clinical study of Pembrolizumab in combination with Sacituzumab govitecan versus Pembrolizumab monotherapy as first-line treatment in participants with PDL-1 TPS greater than or equal to 50 % metastatic NSCLC (Keynote D46/EVOKE-03)

Gilead Sciences, Prot. GS-US-626-6216, STAR-121

A randomized, open-label, phase 3 study to evaluate Zimberelimab and Domvanalimab in combination with chemotherapy versus Pembrolizumab with chemotherapy for the first-line treatment of patients with metastatic NSCLC with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations

Regeneron Ph. Inc.; R2810-ONC-2045; EMPOWERVAX Lung 1

A PHASE 2 STUDY OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) IN COMBINATION WITH BNT116 (FIXVAC LUNG) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 ≥50%

Novocure Prot. LUNAR-2; Syneos Health

Piovital, randomized, open-label study of TTF concomitant with Pembrolizumab and Platin based chemotherapy ort eh treatment of metastatic non-small cell lung cancer.

GSK; Prot. 213823; Galaxies Lung 301

Randomized, Multi-Center, Double-blind, Placebo-controlled, Phase 3 study to investigate safety and efficacy of GSK4428859A in combination with Dostarlimab compared with Placebo in combination with Pembrolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1 selected NSCLC

 

NSCLC Stadium IV – palliativ; Zweitlinientherapie

SEAGEN; Prot. SGNB6A-002

A randomized, phase 3, open-label study to evaluate SGN-B6A compared with Docetaxel in adult subjects with previously treated non-small cell lung cancer

Roche, BO45217, Krascendo-1

A PHASE III, RANDOMIZED, OPEN-LABEL,MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

SCLC Stadium IV – palliativ; Erstlinientherapie

Bristol Myers Squibb; Prot. CA245-0001; Bristol Myers Squibb TIGOS

Randomized, double-blind, multicenter, phase 3 trial of BMS-986489 (BMS-986012 + Nvolumab FDC) in combination with Carboplatin plus Etoposide vs. Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage SCLC

 

SCLC Stadium IV – palliativ; Zweitlinientherapie

G1 Therapeutics; Prot. G1T28-211

A Phase 3, randomized, double-blind, placebo-controlled study of Trilaciclib vs Placebo in patients with ES-SMCL receiving Topotecan chemotherapy

PharmaMar; CUP Lurbinectedin

Compassionate use: Lurbinectedin in previously treated Stage IV SCLC with brain metastases 

 

Pleuramesotheliom - palliativ

 

Novocure GmbH; Prot. Tiger Meso

TTFields in general routine clinical care in patients with pleural mesothelioma study

2. Standort

Krankenhaus St. Elisabeth und St. Barbara Halle
Ansprechpartner: CA Dr. med. Ralf Heine

Kooperationspartner:

Lungenklinik Neustadt
Ansprechpartnerin: CÄ Dr. med. Kathrin Conrad

Universitätsklinikum Halle (Saale)
Ansprechpartner: PD Dr. med. habil. Stephan Eisenmann

Diakonie Krankenhaus Halle
Ansprechpartnerin: Dr. med. Ines Bork

Carl-von-Basedow-Klinikum Saalekreis gGmbH, Standort Querfurt
Ansprechpartner: Dr. med. Klaus-Peter Litwinenko

Gesundheitszentrum Bitterfeld/Wolfen
Ansprechpartnerin: Dr. med. Petra Hampel